Bridging with a single glucocorticoid injection in psoriatic arthritis: Real-world evidence of short-term effectiveness, safety, and enhanced response in high-inflammatory burden patients
A single-dose intramuscular injection of compound betamethasone may provide articular improvements with a favorable short-term safety profile and greater benefits in patients with high-inflammatory burden support its role as a bridging therapy.
Abstract
Background The use of adjunctive systemic glucocorticoids (GC) as bridging therapy in psoriatic arthritis (PsA) remains controversial due to limited disease-specific evidence and safety concerns. Although clinical experience suggests potential benefits in selected patients, clear criteria for appropriate use are lacking. The unique pharmacokinetic profile of intramuscular compound betamethasone offers a bridging strategy but has been insufficiently studied. Objectives To investigate the real-world effectiveness and safety of single intramuscular GC injection as a bridging therapy for active PsA, and identify clinical characteristics associated with greater therapeutic response. Design A retrospective observational comparative study using longitudinal clinical data. Methods Data were derived from the PKUPsA cohort. Patients receiving a single intramuscular compound betamethasone injection alongside background disease-modifying antirheumatic drugs (DMARDs) were compared with controls not receiving GC. Changes in disease activity, patient-reported outcomes, and adverse events were assessed at 1 month and over 6 months. Negative binomial regression and interaction analysis were used to assess treatment effects and explore differential responses. Results Of 183 enrolled patients (81 GC, 102 control), the GC group showed higher baseline tender joint count (TJC), Disease Activity in Psoriatic Arthritis (DAPSA), ESR and CRP, but lower Psoriasis Area and Severity Index (PASI). At month 1, the GC group demonstrated greater SJC improvements (ΔSJC: 1 [0 to 2] vs. 0 [0 to 1], P=0.02). Adjusted negative binomial regression confirmed a conditional effect of GC on SJC at month 1, with Johnson–Neyman analysis indicating significance at baseline SJC > 6.6. Treatment benefits were consistent across subgroups and sustained over 6 months. Reported adverse events, including transient PASI increases, were not attributed to GC. Conclusion A single-dose intramuscular injection of compound betamethasone may provide articular improvements with a favorable short-term safety profile. Greater benefits in patients with high-inflammatory burden support its role as a bridging therapy.
The EULAR/PreS and American College of Rheumatology (ACR) guidelines for Still's disease (SD) were recently published with new therapeutic management strategies to achieve therapeutic targets within a specified timeframe. The early use of interleukin (IL)-1 or IL-6 inhibitors associated with short-term corticosteroids...
Karima Daghor-Abbaci, Oya Köker· Advances in Therapy· 0 citations
In this real-world emulated multicentre clinical trial, bDMARDs showed comparable overall trajectories of short-term effectiveness and long-term treatment persistence in PsA and the identification of partially distinct response patterns may support a more individualised approach to bDMARD selection.
P. Ruscitti, F. Masedu, I. Pantano et al.· Annals of the Rheumatic Dise...· 0 citations
Purpose: This review summarizes the mechanisms of action, safety profiles, and monitoring strategies of the major pharmacological agents currently used to treat rheumatoid arthritis (RA) in Korea.Current concepts: RA is a chronic systemic autoimmune disease characterized by persistent synovial inflammation that can lea...
B. Nam· Journal of Korean Medical As...· 0 citations
Biologic therapies have substantially improved outcomes in moderate-to-severe psoriasis; however, in real-world practice, secondary loss of efficacy - often driven by immunogenicity and ultimately reflected in reduced treatment persistence - remains an important clinical challenge. Although biologic-disease-modifying...
Kah-Hau Kwong, Yang Lo· Zhōnghuá Pífūkē Yīxué Zázhì· 0 citations
AIMS
Subcutaneous (SC) flat-dose infliximab (IFX) biosimilar offers potential advantages over intravenous (IV) weight-based dosing. Prospective pharmacokinetic data and clinical outcomes in inflammatory bowel disease (IBD) are scarce, since drug approval was primarily based on a rheumatoid-arthritis study population co...
Lieke M. J. van de Ven-van Dinter, M. Romberg-Camps, D. Wong et al.· British Journal of Clinical...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.